Skip to content

Clinical trial of Nutraceutical product Power Gummies : hair and nail vitamin.

A parallel arm clinical trial to evaluate safety and efficacy of Power Gummies : hair and nail vitamin; in hair fall reduction, accelerated hair growth, strengthening of hair with overall hair and scalp health improvement in healthy female and male. - NIL

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/10/028698
Enrollment
60
Registered
2020-10-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Power Gummies: Hair and Nail Vitamin: 1 Power Gummy per day for 90 days after each meal. Control Intervention1: NA: NA

Sponsors

Aesthetic Nutrition Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Male and Female subjects in general good health, subjects in the age group 18-40 years, subjects willing to to give written informed consent and agree to come for a regular follow up visit, subjects not participated in a similar investigations in the past two weeks, subjects complaining of hair fall and damage, subjects who are not on crash dieting, subjects who agree to not to change the brand of currently used hair color, dye, treatment etc., if during the study term, subjects willing to refrain from any type of hair treatment like head massage, oil application, perming, etc. during the study duration, subjects with at least of two of following complaints- dry damaged hair, brittle and thin hair, premature greying of hair, scalp related complaints like itching, dandruff or irritation

Exclusion criteria

Exclusion criteria: Subjects who are undergoing hair growth treatment within 3 months before screening into the study. Subjects having any active scalp disease which may interfere in the study. Subjects on treatment for active acne Subjects with history or active phase of malignancy and chemotherapy therefore. Subjects who have history of alcoholism and/ or psychiatric disorder including trichotillomania. Subjects who have had hair transplant. Subjects who take pharmaceutical product which cause hirsutism. Subjects on oral hair growth medications which will compromise the study. Subjects who are pregnant lactating or nursing as established with medical history. Chronic illness which may influence the study. Subjects participating in other similar cosmetic or therapeutic trial within last two weeks Any history of underlying uncontrolled medical illness including diabetes mellitus, hypertension, HIV, hepatitis, severe anemia, serious disorder of heart and respiratory apparatus or any other serious medical illness

Design outcomes

Primary

MeasureTime frame
Change in the number of terminal hairs and vellus hairs in the target area of the scalp from baseline to end of study identified by Phototrichograms. Reduction change in the shedding range of the hair in the â??60 Second Hair Comb testâ?? from baseline to end of the study. (Hair strength) Change in folliscopic measurement of hair density and hair diameter (Hair Density), Change in nail growth and satisfaction scale on nail health Timepoint: Baseline, day 30, day 60 and day 90

Secondary

MeasureTime frame
Improvement in the Hair Assessment Questionnaire, Improvement in the Modified hair wash test (Brittleness and hair loss after washing), Improvement in quality of hair, VAS- Visual analog scale scalp related complaints like itching, dandruff or irritation (Scalp health),Premature graying, Assessment of tolerability of study drug by assessing adverse events, serious adverse events during the study period, Assessment of Global evaluation of overall improvement in scalp and hair. Timepoint: Baseline, day 30, day 60 and day 90

Countries

India

Contacts

Public ContactMr Kapil Mittal

Mprex Healthcare Pvt. Ltd.

gayatri.mbgindia@gmail.com8554912644

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026